SEP 30, 2015 10:30 AM PDT
The Evolving Role of Image-Guided Prostate Cancer Targeting and Ablation: Moving Towards Personalized Medicine
Presented at the Cancer Research and Oncology Virtual Event
20 1287

Speakers:
  • Professor of Surgery, Director, Society of Urologic Oncology Program, Director, Genitourinary Program on Focal Therapy, Duke Cancer Institute, Duke University Medical Center
    Biography
      Thomas J. Polascik, M.D. is Professor in the Duke Cancer Institute, the Department of Surgery at the Duke University Medical Center, Durham, NC. Dr. Polascik trained at the Brady Urological Institute, the Johns Hopkins Hospital in Baltimore Maryland. After finishing his residency under the tutelage of Patrick C. Walsh M.D. he did an oncology fellowship under the mentorship of Alan W. Partin M.D. PhD. He then joined the faculty at Duke University and has been there since 1998. His clinical practice and research interests incorporate both prostate and kidney cancer.

      In 2006 he developed an interest in the nascent field of focal therapy for prostate cancer. He is the founder and director, the International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer that began at Duke in 2008. The symposium has brought together investigators and clinicians from all regions of the world and the meeting alternates between North America and Europe with Co-chairs Drs Jean de la Rosette and Indy Gill. This year marked the eighth annual meeting to be held in the Netherlands in June 2015.

      Dr. Polascik is the Editor of Imaging and Focal Therapy of Early Prostate Cancer released in 2013. He is the director of the Society of Urologic Oncology program at Duke and also the Genitourinary Program on Focal Therapy at the Duke Cancer Institute. His research interests include the development of image-guided therapies for early prostate cancer, the development of prostate cancer imaging techniques and minimally invasive treatment options for both prostate and kidney cancer. He has published over 250 manuscripts and book chapters. He has held positions on several boards of directors, advisory boards, and has been active in the North Carolina Urological Association and the Board of Directors with the Southeastern American Urological Association. He is an avid ad hoc reviewer for a number of journals and currently holds a NIH R-O1 and Department of Defense Grant for research.
    • Assistant Professor of Urology and Population Health, NYU School of Medicine
      Biography
        Dr. Stacy Loeb is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prostate cancer. Dr. Loeb completed her urology residency training at Johns Hopkins and subsequently received a Masters of Science in Comparative Effectiveness Research at NYU. She has a K07 grant from the National Cancer Institute to study active surveillance for prostate cancer.
        Dr. Loeb is an internationally recognized expert in prostate cancer with more than 225 peer-reviewed published articles and 8 book chapters. She is on the Editorial Board for the British Journal of Urology International, European Urology, Urology Practice and Reviews in Urology. Dr Loeb authored the chapter on "Early Detection, Diagnosis, and Staging of Prostate Cancer" for Campbell-Walsh Urology. Dr. Loeb also frequently gives international lectures on prostate cancer, and hosts the Men's Health Show on Sirius XM 81 satellite radio.
      • Assistant Professor of Radiology, Director, Abdominal Imaging Fellowship Program, Duke University School of Medicine
        Biography
          Dr. Rajan T. Gupta, MD, is an Assistant Professor of Radiology in the Division of Abdominal Imaging at Duke University Medical Center, as well as the Director of the Abdominal Imaging Fellowship Program and a Faculty physician in the Duke Cancer Institute. Since 2009, he has been a faculty member in the Department of Radiology at Duke. Dr. Gupta has coauthored over 40 peer-reviewed publications. He has been awarded two Duke-Coulter Translational Research Grants as Clinical Principal Investigator, the most recent of which was entitled, "Registration of Multi-parametric MR and Quantitative Shear Wave Elasticity Images for Focal Prostate Cancer Procedures." He is a member of the Duke Cancer Institute Multi-Disciplinary Prostate Cancer Strategy Group. He has been an invited Refresher Course speaker at the Radiological Society of North America national meeting for the past 5 years and has been an invited Visiting Professor at institutions such as George Washington University, MD Anderson Cancer Center, The Mayo Clinic, and the University of Chicago. His recent published works have been focused on the comparison of multiparametric MRI (mpMRI) at 3 Tesla with the Partin Tables in assessment of organ confined prostate cancer, the effects of dedicated education on reader performance of mpMRI interpretation, and the assessment/development of a novel ultrasonic technique (Acoustic Radiation Force Impulse Imaging - ARFI) in the detection/characterization of prostate cancer in conjunction with his colleagues in the Department of Biomedical Engineering at Duke.

        Abstract:
        The management of prostate cancer (PCa) continues to evolve and does so at a rapid rate. Research and technological developments continue to refine our definitions and management of this complex disease. As we acquire a greater understanding of the natural history of PCa and its biology, the prevention of overtreatment has shaped a new era with the move from more radical treatments to the adoption of active surveillance (AS) and advancement of focal therapy (FT). An important factor in this move to less invasive therapies is the expanded role that multiparametric magnetic resonance imaging (mpMRI) is playing in the detection and characterization of clinically significant prostate cancer. We are now able to locate and monitor cancers more effectively than ever before with the inclusion of functional imaging sequences such as diffusion weighted imaging and dynamic contrast enhanced imaging. These capabilities combined with promising results from current prospective studies have changed the face of FT. Our presentation will focus on how to utilize mpMRI-assigned targets for image-guided biopsy and therapy in our move to a more personalized approach to the patient with PCa.

        Show Resources
        Loading Comments...